Európska únia - portugalčina - EMA (European Medicines Agency)

alnylam netherlands b.v. - lumasiran sodium - hyperoxaluria, primary - outro aparelho digestivo e metabolismo produtos, - treatment of primary hyperoxaluria type 1 (ph1) in all age groups.

Európska únia - portugalčina - EMA (European Medicines Agency)

mylan ireland limited - sugammadex sodium - bloqueio neuromuscular - todos os outros produtos terapêuticos - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Európska únia - portugalčina - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Európska únia - portugalčina - EMA (European Medicines Agency)

gilead sciences ireland unlimited company - lenacapavir sodium - infecções por hiv - antivirais para uso sistêmico - sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4. 2 e 5. sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4. 2 e 5.

Európska únia - portugalčina - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - sugammadex sodium - bloqueio neuromuscular - todos os outros produtos terapêuticos - reversão do bloqueio neuromuscular induzido por rocurônio ou vecurônio. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Európska únia - portugalčina - EMA (European Medicines Agency)

extrovis eu ltd. - sugammadex sodium - bloqueio neuromuscular - todos os outros produtos terapêuticos - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Brazília - portugalčina - ANVISA (Agência Nacional de Vigilância Sanitária)

laboratÓrio teuto brasileiro s/a - cloreto de sÓdio - outros produtos para o aparelho respiratorio

Brazília - portugalčina - ANVISA (Agência Nacional de Vigilância Sanitária)

farmoquÍmica s/a - cloreto de sÓdio - descongestionantes nasais topicos

Brazília - portugalčina - ANVISA (Agência Nacional de Vigilância Sanitária)

natulab laboratÓrio s.a - cloreto de sÓdio -

Brazília - portugalčina - ANVISA (Agência Nacional de Vigilância Sanitária)

uniÃo quÍmica farmacÊutica nacional s/a - cloreto de sÓdio - descongestionantes nasais topicos